Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jason Coloma
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 141
- Beta
- 2.03
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 11.05
Financials
Revenue
$0.00-100.0%Net Income
$-47.97MEBITDA
$-46.61MFree Cash Flow
$-33.13MEPS (diluted)
$-0.79Shares Outstanding (diluted)
60.86M+39.0%Operating Expenses
$51.52MCash & Debt
$389.66MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-131.12M | $-3.05 |
| 2024 | $167.50M | $52.23M | $0.08 |
| 2023 | $0.00 | $-100.42M | $-2.29 |
| 2022 | $0.00 | $-114.94M | $-2.63 |
Valuation
MAZEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-47.06%Social Signal Score
Mentions (10)
- Newszacks.com·18d ago·Negative
Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know The average of price targets set by Wall Street analysts indicates a potential upside of 93.9% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
Maze Therapeutics to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in three upcoming investor conferences:
View source ↗ - Newszacks.com·34d ago·Positive
What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock Maze Therapeutics, Inc. (MAZE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newszacks.com·34d ago·Neutral
How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39% The average of price targets set by Wall Street analysts indicates a potential upside of 123.4% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
…therapeutic potential of SLC6A19 inhibition in chronic kidney disease SOUTH SAN FRANCISCO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that the company will present data supporting its lead programs, MZE829 and MZE782, during the American Society of Nephrology (ASN) Kidney Week, being held October 21–25, 20…
View source ↗ - Newsfool.com·72d ago·Negative
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 Chief Medical Officer Harold Bernstein sold 9,705 shares for ~$255,000 on September 4, 2026. The transaction involved shares equal to 100% of the insider's directly held common stock before the filing.
View source ↗ - Newsglobenewswire.com·81d ago·Neutral
…e Therapeutics to Participate in Three Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in three upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference; fireside chat on Wednesday, September 9, 2026…
View source ↗ - Newsseekingalpha.com·88d ago·Neutral
Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist Maze Therapeutics, Inc. has advanced two lead precision medicine programs, MZE782 for PKU and MZE829 for APOL1-mediated kidney disease, with significant clinical progress. MZE782 demonstrated a best-in-class pharmacodynamic profile in Phase 1, supporting a transformative potential for PKU management; Phase 2 is set for mid-2026. MZE829 achieved strong uACR reductions in early Phase 2 data for AMKD, but faces competitio
View source ↗ - Newsglobenewswire.com·101d ago·Neutral
Maze Therapeutics Announces Appointments to Its Board of Directors Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze's Board of Directors, adding to the Company's deep bench of clinical and industry experience
View source ↗ - Newsglobenewswire.com·103d ago·Positive
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $495 million in cash, cash equivalents and marketable securities supports expected runway into 2029 SOUTH SAN
View source ↗
Earnings
Wed, Mar 24(in 4 months)
Consensus estimate $-0.84 per share
Typical surprise -0.7% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$-0.79 vs $-0.76miss
- Wed, Aug 12$-0.76 vs $-0.72miss
- Tue, May 12$-0.45 vs $-0.43miss
- Wed, Mar 25$-0.65 vs $-0.73beat
- Thu, Nov 6$-0.66 vs $-0.74beat
- Tue, Aug 12$-0.77 vs $-0.79beat
Estimates and results for MAZE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MAZE officers and directors.
- Bought
- —
- Sold
- $11.4m
0 trades
56 trades
- Coloma Jason Vsold
- Coloma Jason Vsold
- Coloma Jason Vsold
- Coloma Jason Vsold
- Dandekar Atulsold
- Coloma Jason Vsold
- Coloma Jason Vsold
- Bernstein Haroldsold
44 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MAZE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
